AvenCell
PrivateLast Round
Grant
Jun 30, 2025
Total Funding Raised
$402M
Company Overview
AvenCell is a biotechnology company that develops next-generation, switchable, allogeneic CAR-T cell immunotherapies for the treatment of hard-to-treat cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AvenCell Comparables
Compare AvenCell with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Wugen | 82% | |
| Allotera Therapeutics | 82% | |
| Bioheng Therapeutics | 81% | |
AvenCell Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jun 30, 2025 | ||||
| Series B | Oct 22, 2024 | ||||
| Series A | Jun 22, 2021 |
Key People
Founding team and executive leadership
AvenCell Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Japan Agency for Medical Research and Development | Grant |
| Cellex Cell Professionals GmbH | Series A |
| F-Prime Capital | Series B |
| Eight Roads Ventures | Series B |
| Novo Holdings | Series B |
| Eight Roads Ventures Japan | Series B |
| F-Prime Capital | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 30, 2025
$40M grant received from Japan Agency for Medical Research and Development.
- Jun 30, 2025
Dual-antigen CAR-T therapy AVC203 for B-cell Lymphomas now at IND stage.
AvenCell Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about AvenCell's valuation, stock price, and market status.